Skip to content
Screener

Arrowhead Research ARWR Stock-Based Comp

Stock-Based Comp at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$45.6M+53.6%
ALN
Alnylam PharmaceuticalsALNY
$86.63M-22.4%
Assembly Biosciences logo
Assembly BiosciencesASMB
$1.12M+56.7%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$1.36M-61.9%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$19.04M-28.6%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$13.08M+0.5%

Segments

By segment

See full
Operating Segment$8.37M+2.9%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemSix Months Ended March 31, 2026Six Months Ended March 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income$(109,328)$192,645
Adjustments to reconcile net (loss) income to net cash flow from operating activities
Stock-based compensation36,04131,236
Depreciation and amortization12,75811,319
Accretion of available-for-sale securities premiums/discounts(2,515)(2,788)
Amortization of convertible notes issuance costs657
Realized gain on investments(19)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's stock-based comp?
Arrowhead Research (ARWR) reported stock-based comp of $16.67M in Q1 2026.
How has Arrowhead Research's stock-based comp changed year-over-year?
Arrowhead Research's stock-based comp increased by 4.0% year-over-year, from $16.03M to $16.67M.
What is the long-term trend for Arrowhead Research's stock-based comp?
Over 4 years (2021 to 2025), Arrowhead Research's stock-based comp has grown at a -4.7% compound annual growth rate (CAGR), from $76.67M to $63.37M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Arrowhead Research's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude